- A biotech startup, Life Biosciences, has administered the first human injection of a cellular reprogramming therapy aimed at reversing age-related diseases.
- The injection targets glaucoma in the eye, marking a pivotal trial for epigenetic reprogramming, which seeks to make aging cells behave more youthfully.
- Key figures like Jeff Bezos and Sam Altman, along with pharmaceutical companies, are investing heavily in this longevity science, previously tested only in animals.
- Cellular reprogramming, pioneered by Shinya Yamanaka's Nobel-winning work, involves using proteins to rejuvenate cells without fully reverting them to stem cells.
- Life Biosciences uses three of the four Yamanaka factors, omitting one linked to cancer, and controls the therapy with a doxycycline on/off switch for safety.
- Potential applications extend beyond vision and muscle to systemic benefits, though risks include cancer and the technology is still in early stages.
- The trial includes nearly 20 patients across U.S. clinics, focusing on eye diseases, with results expected over six months.